It is currently Fri Oct 28, 2016 12:42 pm
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) ... SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with AL...RICHMOND Calif. Sept. 3 /- SangamoBioScience...Sangamo's drug SB-509 is an injectable formulation of a plasmidenco...
SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS
RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) ...
-- Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif(R) on disease activity as measured by MRI after 16 weeks of treatment
-- Data presented at late-breaking session of the World Congress on
Treatment and Research in Multiple ...
Total posts 234650 • Total topics 25267 • Total members 16465